Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnosticsGlobeNewsWire • 05/07/26
Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026Business Wire • 04/30/26
Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026GlobeNewsWire • 04/30/26
Roche: Policy Overhang Clears, Fundamentals Intact, Upside Remains Limited But PositiveSeeking Alpha • 04/28/26
Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME' CampaignBusiness Wire • 04/24/26
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss francGlobeNewsWire • 04/23/26
Roche Highlights Gazyva Progress, Reports Data on Enspryng, MS DrugZacks Investment Research • 04/22/26
Roche submits multiple sclerosis drug fenebrutinib to regulators despite patient deathsReuters • 04/22/26
Roche's fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMSGlobeNewsWire • 04/21/26
Genentech's Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMSBusiness Wire • 04/21/26
Roche's ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGADGlobeNewsWire • 04/21/26
Genentech's Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGADBusiness Wire • 04/21/26
FDA accepts application for Roche's Gazyva/Gazyvaro for the treatment of the most common form of lupusGlobeNewsWire • 04/21/26
FDA Accepts Application for Genentech's Gazyva for the Treatment of the Most Common Form of LupusBusiness Wire • 04/21/26
Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosisGlobeNewsWire • 04/13/26
C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billionReuters • 04/09/26